Tractocile 37.5 mg/5ml concentrate for solution for infusion

  • Name:

    Tractocile 37.5 mg/5ml concentrate for solution for infusion

  • Company:
    info
  • Active Ingredients:

    Atosiban Acetate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Summary of Product Characteristics last updated on medicines.ie: 15/2/2016
print

Print ViewKeyword Search SmPC

Ferring Ireland Limited

Ferring Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Cortiment 9mg prolonged release tablets Active Ingredients Budesonide
Medicine Name DDAVP Desmopressin 100 micrograms/ml Nasal drops,solution Active Ingredients Desmopressin Acetate
Medicine Name DDAVP/Desmopressin 4 micrograms/ml Solution for Injection Active Ingredients Desmopressin Acetate
Medicine Name Desmospray, Desmopressin Nasal Spray Active Ingredients Desmopressin Acetate
Medicine Name Desmotabs Melt 120 micrograms oral lyophilisate Active Ingredients Desmopressin Acetate
Medicine Name Desmotabs Melt 240 micrograms oral lyophilisate Active Ingredients Desmopressin Acetate
Medicine Name Desmotabs Melt 60 micrograms oral lyophilisate Active Ingredients Desmopressin Acetate
Medicine Name FIRMAGON 120 mg powder and solvent for solution for injection Active Ingredients degarelix acetate
Medicine Name FIRMAGON 80 mg powder and solvent for solution for injection Active Ingredients degarelix acetate
Medicine Name Glypressin 1 mg Powder and Solvent for Solution for Injection Active Ingredients Terlipressin acetate
Medicine Name Glypressin 1 mg/ 8.5 ml solution for injection Active Ingredients Terlipressin acetate
Medicine Name Gonapeptyl Depot 3.75 mg powder and solvent for suspension for injection Active Ingredients triptorelin acetate
Medicine Name Lutinus 100 mg Vaginal Tablets Active Ingredients Progesterone
Medicine Name Menopur 1200IU powder and solvent for solution for injection Active Ingredients Menotrophin
Medicine Name Menopur 600IU powder and solvent for solution for injection Active Ingredients Menotrophin
Medicine Name Menopur 75IU Powder and Solvent for Solution for Injection. Menotrophin (HMG) Active Ingredients Menotrophin
Medicine Name Noqturina 25 microgram oral lyophilisate Active Ingredients Desmopressin Acetate
Medicine Name Noqturina 50 microgram oral lyophilisate Active Ingredients Desmopressin
Medicine Name Nordurine 0.1 mg Tablets Active Ingredients Desmopressin Acetate
Medicine Name Nordurine 0.2mg Tablets Active Ingredients Desmopressin Acetate
Medicine Name Pabal 100 micrograms/ml solution for injection Active Ingredients Carbetocin
Medicine Name Pentasa 1 g Prolonged-release Tablets Active Ingredients Mesalazine
Medicine Name Pentasa 1 g Suppositories Active Ingredients Mesalazine
Medicine Name Pentasa 10 mg/ml Rectal Suspension Active Ingredients Mesalazine
Medicine Name Pentasa 500 mg Prolonged Release Tablets Active Ingredients Mesalazine
1 - 0 of 35 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 February 2016 PIL

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 7 - Marketing authorisation holder

Free text change information supplied by the pharmaceutical company

Section 4.8: reporting of side effects information added
Section 7: Telephone number for MA holder added

Updated on 15 February 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 15 February 2016 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8: reporting of side effects information added
Section 7: Telephone number for MA holder added

Updated on 21 March 2013 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.4 - Special precautions for storage

Free text change information supplied by the pharmaceutical company

Section 4.2:

Deletion of text:
There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys. Renal impairment is not likely to warrant a dose adjustment, since only a small extent of atosiban is excreted in the urine. In patients with impaired hepatic function, atosiban should be used with caution.

Addition of text:

Patients with renal or hepatic impairment

There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys. Renal impairment is not likely to warrant a dose adjustment, since only a small extent of atosiban is excreted in the urine. In patients with impaired hepatic function, atosiban should be used with caution.

 

Paediatric population

The safety and efficacy of Tractocile in pregnant women aged less than 18 years have not been established.

No data are available.

Method of administration
For instructions on preparation of hte medicinal product before administration, see section 6.6.


Section 4.4:

 

Addition of text:
Multiple pregnancy and tocolytics like calcium channel blockers and betamimetics are known to be associated with increased risk of pulmonary oedema. Therefore, atosiban should be used with caution in case of multiple gestations and/or concomitant administration of other tocolytics.


Section 4.8:
Addition of text:
Respiratory events like dyspnoea and pulmonary oedema, particularly in association with concomitant administration of other tocolytics like calcium antagonists and beta-mimetics and/or multiple pregnancy, have been reported post-marketing.

Section 6.4:
Addition of text:

For storage conditions after first opening of the medicinal product, see section 6.3.

Updated on 21 March 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2:

Deletion of text:
There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys. Renal impairment is not likely to warrant a dose adjustment, since only a small extent of atosiban is excreted in the urine. In patients with impaired hepatic function, atosiban should be used with caution.

Addition of text:

Patients with renal or hepatic impairment

There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys. Renal impairment is not likely to warrant a dose adjustment, since only a small extent of atosiban is excreted in the urine. In patients with impaired hepatic function, atosiban should be used with caution.

 

Paediatric population

The safety and efficacy of Tractocile in pregnant women aged less than 18 years have not been established.

No data are available.

Method of administration
For instructions on preparation of hte medicinal product before administration, see section 6.6.


Section 4.4:

 

Addition of text:
Multiple pregnancy and tocolytics like calcium channel blockers and betamimetics are known to be associated with increased risk of pulmonary oedema. Therefore, atosiban should be used with caution in case of multiple gestations and/or concomitant administration of other tocolytics.


Section 4.8:
Addition of text:
Respiratory events like dyspnoea and pulmonary oedema, particularly in association with concomitant administration of other tocolytics like calcium antagonists and beta-mimetics and/or multiple pregnancy, have been reported post-marketing.

Section 6.4:
Addition of text:

For storage conditions after first opening of the medicinal product, see section 6.3.

Updated on 5 September 2011 PIL

Reasons for updating

  • Change to section 6.3 - Shelf life

Free text change information supplied by the pharmaceutical company

In section 6.3, the shelf-life has been changed from 2 to 4 years

Updated on 5 September 2011 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 6.3, the shelf-life has been changed from 2 to 4 years

Updated on 10 June 2010 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Free text change information supplied by the pharmaceutical company

Section 1: Name changed to 'Tractocile 37.5 mg/5 ml concentrate for solution for infusion'

Section 2: Updated to 'Each vial of 5 ml solution contains 37.5 mg atosiban (as acetate). Each ml of solution contains 7.5 mg atosiban.'

Section 4.2:  Updated warning on hepatic function.

Section 4.4: Updated information on impaired renal and hepatic function.

Section 4.5:  Updated information indicating that interaction studies were performed with labetalol adn betamethasone and no clinically relevant interaction was found.

Section 4.6: Lactation statement updated 'If during pregnancy the woman is already breast-feeding an earlier child, then breast-feeding should be discontinued during treatment with TRACTOCILE, since the release of oxytocin during breast-feeding may augment uterine contractility, and may counteract the effect of tocolytic therapy.'

Section 4.8: Undesirable effects presented in MedDra format.  Statement included: 'The observed adverse reactions were generally of a mild severity. The most commonly reported adverse reaction in the mother is nausea (14 %).'

Updated on 10 June 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 1: Name changed to 'Tractocile 37.5 mg/5 ml concentrate for solution for infusion'

Section 2: Updated to 'Each vial of 5 ml solution contains 37.5 mg atosiban (as acetate). Each ml of solution contains 7.5 mg atosiban.'

Section 4.2:  Updated warning on hepatic function.

Section 4.4: Updated information on impaired renal and hepatic function.

Section 4.5:  Updated information indicating that interaction studies were performed with labetalol adn betamethasone and no clinically relevant interaction was found.

Section 4.6: Lactation statement updated 'If during pregnancy the woman is already breast-feeding an earlier child, then breast-feeding should be discontinued during treatment with TRACTOCILE, since the release of oxytocin during breast-feeding may augment uterine contractility, and may counteract the effect of tocolytic therapy.'

Section 4.8: Undesirable effects presented in MedDra format.  Statement included: 'The observed adverse reactions were generally of a mild severity. The most commonly reported adverse reaction in the mother is nausea (14 %).'

Updated on 14 November 2008 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Free text change information supplied by the pharmaceutical company

Section 6:  Change in MA holder

Updated on 14 November 2008 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 6:  Change in MA holder

Updated on 27 August 2007 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 27 August 2007 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 5 July 2005 PIL

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Updated on 5 July 2005 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 26 June 2003 PIL

Reasons for updating

  • New SPC for medicines.ie

Updated on 26 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)